Cargando…

Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats

Osteoporosis patients with chronic kidney disease (CKD) are becoming common in our superaging society. Renal dysfunction causes phosphorus accumulation in the circulating plasma and leads to the development of CKD-mineral bone disorder (MBD). We have previously reported that type III Pi transporter-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asada, Yohei, Takayanagi, Takeshi, Kawakami, Tsukasa, Tomatsu, Eisuke, Masuda, Atsushi, Yoshino, Yasumasa, Sekiguchi-Ueda, Sahoko, Shibata, Megumi, Ide, Tomihiko, Niimi, Hajime, Yaoita, Eishin, Seino, Yusuke, Sugimura, Yoshihisa, Suzuki, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854176/ https://www.ncbi.nlm.nih.gov/pubmed/31772574 http://dx.doi.org/10.1155/2019/4194853

Ejemplares similares

Short-Term High-Starch, Low-Protein Diet Induces Reversible Increase in β-cell Mass Independent of Body Weight Gain in Mice
por: Masuda, Atsushi, et al.
Publicado: (2019)

Dynamic changes of podocytes caused by fibroblast growth factor 2 in culture
por: Yaoita, Eishin, et al.
Publicado: (2021)

Nutritional status of calcium and other bone-related nutrients in Japanese type 2 diabetes patients
por: Tomastu, Eisuke, et al.
Publicado: (2016)

Effects of Risedronate on Osteoarthritis of the Knee
por: Iwamoto, Jun, et al.
Publicado: (2010)

High Protein Diet Feeding Aggravates Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides
por: Ueno, Shinji, et al.
Publicado: (2022)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Blockade of glucagon increases muscle mass and alters fiber type composition in mice deficient in proglucagon‐derived peptides
por: Ueno, Shinji, et al.
Publicado: (2023)

Efficacy of topical risedronate and risedronate - Eudragit E complex in a model of cutaneous leishmaniasis induced by Leishmania (Leishmania) amazonensis
por: Peralta, Ma. Florencia, et al.
Publicado: (2021)

Risedronate inhibits human osteosarcoma cell invasion
por: Xin, Zeng Feng, et al.
Publicado: (2009)

Crystallization Products of Risedronate with Carbohydrates and Their Substituted Derivatives (†)
por: Kos, Jiri, et al.
Publicado: (2011)

Preparation of Risedronate Nanoparticles by Solvent Evaporation Technique
por: Vaculikova, Eliska, et al.
Publicado: (2014)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Risedronate-loaded aerogel scaffolds for bone regeneration
por: El-Wakil, Nahla, et al.
Publicado: (2022)

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
por: Cho, Yong Ho, et al.
Publicado: (2020)

An open‐label randomized study of the relative absorption of gastro‐resistant risedronate taken fasted or with food versus immediate‐release risedronate
por: Kleinermans, Diane, et al.
Publicado: (2022)

Sustained anti-osteoporotic action of risedronate compared to anti-RANKL antibody following discontinuation in ovariectomized mice
por: Omiya, Toshinobu, et al.
Publicado: (2020)

Expression of Tight Junction Protein Claudin-1 in Human Crescentic Glomerulonephritis
por: Koda, Ryo, et al.
Publicado: (2014)

Effects of risedronate on fracture risk in postmenopausal women with osteopenia
por: Siris, E. S., et al.
Publicado: (2007)

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
por: Bobba, Raja, et al.
Publicado: (2007)

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
por: Eisman, John A., et al.
Publicado: (2023)

Twisted Gastrulation, a BMP Antagonist, Exacerbates Podocyte Injury
por: Yamada, Sachiko, et al.
Publicado: (2014)

Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
por: Shigematsu, Takashi, et al.
Publicado: (2017)

A novel podocyte gene, semaphorin 3G, protects glomerular podocyte from lipopolysaccharide-induced inflammation
por: Ishibashi, Ryoichi, et al.
Publicado: (2016)

Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate
por: Matsumoto, Y., et al.
Publicado: (2009)

Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis
por: Gates, Brian J., et al.
Publicado: (2012)

The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation
por: Valenti, Maria Teresa, et al.
Publicado: (2010)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009)

Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis
por: Permuy, María, et al.
Publicado: (2014)

Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole
por: Monda, Vincenzo, et al.
Publicado: (2017)

SUN-LB66 Oral Risedronate Treatment in Children With Osteogenesis Imperfecta
por: Nguyen, Antoine T, et al.
Publicado: (2020)

Histomorphometric Effects of 2% Risedronate Gel on Calvarial Bone Defects in Rabbits
por: Aghayan, Shabnam, et al.
Publicado: (2021)

Twist1 in podocytes ameliorates podocyte injury and proteinuria by limiting CCL2-dependent macrophage infiltration
por: Ren, Jiafa, et al.
Publicado: (2021)

Pancreas transplantation improves the quality of life of Japanese type 1 diabetes patients with diabetic kidney disease
por: Fujisawa-Tanaka, Chika, et al.
Publicado: (2023)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: Moro-Álvarez, María J, et al.
Publicado: (2008)

Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
por: Kinov, Plamen, et al.
Publicado: (2012)

Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women
por: Osaki, M., et al.
Publicado: (2011)

Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization
por: Jung, Il-Woo, et al.
Publicado: (2014)

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
por: Tanaka, Mizue, et al.
Publicado: (2014)

Podocytes
por: Reiser, Jochen, et al.
Publicado: (2016)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qtorpnll3u9aji8ps0ajtoev59